Commentary: The PROactive study - The glass is half full

被引：14

作者：

Fonseca, V

Jawa, A

Asnani, S

机构：

[1] Tulane Univ, Med Ctr, Hlth Sci Ctr, New Orleans, LA 70112 USA

[2] King Edward Med Coll, Lahore 54000, Pakistan

来源：

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2006年 / 91卷 / 01期

关键词：

D O I：

10.1210/jc.2005-2450

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：25 / 27

页数：3

共 10 条

[1] The Prospective Pioglitazone Clinical Trial in Macrovascuar Events (PROactive) - Can ploglitazone reduce cardiovascular events in diabetes? - Study design and baseline characteristics of 5,238 patients [J].

Charbonnel, B ;

Dormandy, J ;

Erdmann, E ;

Massi-Benedetti, M ;

Skene, A .

DIABETES CARE, 2004, 27 (07) :1647-1653

[2] The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm [J].

Dandona, P ;

Aljada, A ;

Mohanty, P .

DIABETOLOGIA, 2002, 45 (06) :924-930

[3] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[4] Nontraditional risk factors for cardiovascular disease in diabetes [J].

Fonseca, V ;

Desouza, C ;

Asnani, S ;

Jialal, I .

ENDOCRINE REVIEWS, 2004, 25 (01) :153-175

[5] How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? [J].

Freemantle, N .

BRITISH MEDICAL JOURNAL, 2005, 331 (7520) :836-838

[6] Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].

Grundy, SM ;

Cleeman, JI ;

Daniels, SR ;

Donato, KA ;

Eckel, RH ;

Franklin, BA ;

Gordon, DJ ;

Krauss, RM ;

Savage, PJ ;

Smith, SC ;

Spertus, JA ;

Costa, F .

CIRCULATION, 2005, 112 (17) :2735-2752

[7] Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes [J].

Jawa, AA ;

Fonseca, VA .

CARDIOLOGY CLINICS, 2005, 23 (02) :119-+

[8] Thiazolidinedione use, fluid retention, and congestive heart failure [J].

Nesto, RW ;

Bell, D ;

Bonow, RO ;

Fonseca, V ;

Grundy, SM ;

Horton, ES ;

Le Winter, M ;

Porte, D ;

Semenkovich, CF ;

Smith, S ;

Young, LH ;

Kahn, R .

DIABETES CARE, 2004, 27 (01) :256-263

[9]

NISSEN SE, 2005, JAMA 1020

[10] The PROactive study:: some answers, many questions [J].

Yki-Järvinen, H .

LANCET, 2005, 366 (9493) :1241-1242

← 1 →